Warnings Regarding Nuclear Cardiac Stress Test Agents Issued By The FDA
December 10, 2013
The U.S. Food and Drug Administration (FDA) has issued a warning about health risks that are associated with the use of certain medications given to patients during cardiac nuclear stress tests. The Drug Injury Attorneys with Ferrer, Poirot & Wansbrough explain officials have stated patients who are given dosages of Lexiscan (regadenoson) and Adenoscan (adenosine) are at a greater risk of a heart attack or death.
An FDA Press Release stated the medications work by dilating the arteries of the heart to increase blood flow. Blood then makes its way to healthier areas of the body, allowing doctors to recognize areas where blockages may be present.
The problem with these medications is that the increase in blood flow has been associated with causing some patients to suffer heart attacks, which in a number of cases has resulted in patients’ deaths.
The FDA has addressed these issues though by calling for trained medical professionals and resuscitation equipment to be present any time the medication is administered to a patient. Furthermore, updates and changes have been made to the products’ warning labels.
The team of attorneys with Ferrer, Poirot & Wansbrough are aware of the serious dangers a Lexiscan Drug Injury can pose. That is why the firm suggests anyone who has been harmed by the product discuss their legal options with an attorney immediately.